EI
ONCE

EAM Investors’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

EAM Investors’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-27,445
Closed -$2.45M – 380
2017
Q3 		$2.45M Buy
+27,445
New +$2.08M 0.33% 122
2015
Q3 		– Sell
-15,426
Closed -$930K – 378
2015
Q2 		$930K Sell
15,426
-2,528
-14% -$167K 0.11% 299
2015
Q1 		$1.39M Buy
+17,954
New +$1.03M 0.16% 243

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

EAM Investors's ONCE Position: Q4 2017 in Review

EAM Investors sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2017, closing a stake of 27,445 shares — an estimated $2.45M sold.

EAM Investors first reported a position in ONCE in Q1 2015 and held it in 3 quarters. The position peaked at $2.45M in Q3 2017. 160 funds tracked by Wall St. Rank hold ONCE as of Q4 2017.

  • EAM Investors reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • EAM Investors sold 27,445 Spark Therapeutics, Inc. Common Stock shares in Q4 2017, an estimated $2.45M.
  • EAM Investors first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 3 quarters.
  • EAM Investors's Spark Therapeutics, Inc. Common Stock position peaked at $2.45M in Q3 2017.
  • 160 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2017.

Based on EAM Investors's 13F filing for Q4 2017, filed 12 Feb 2018.